{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:12:06Z","timestamp":1792707126299,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005297","name":"Uniwersytet Medyczny w Bialymstoku","doi-asserted-by":"publisher","award":["B.SUB.25.426"],"award-info":[{"award-number":["B.SUB.25.426"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-33271-5","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T06:26:28Z","timestamp":1766211988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Serum cytokine inflammatory profile in children with ulcerative colitis during 6-month follow-up"],"prefix":"10.1038","volume":"16","author":[{"given":"Katarzyna","family":"Zdanowicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Maciejczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Jamio\u0142kowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz Marek","family":"Lebensztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Daniluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"issue":"10080","key":"33271_CR1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L. & Colombel, J. F. Ulcerative colitis. Lancet 389 (10080), 1756\u20131770 (2017).","journal-title":"Lancet"},{"issue":"2","key":"33271_CR2","first-page":"416","volume":"21","author":"K Zdanowicz","year":"2025","unstructured":"Zdanowicz, K. et al. Evaluation of microbiome composition combined with serum untargeted metabolomic profiling in newly diagnosed children with inflammatory bowel disease. Arch. Med. Sci. 21 (2), 416\u2013424 (2025).","journal-title":"Arch. Med. Sci."},{"issue":"2","key":"33271_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jgh.16431","volume":"39","author":"R Nambu","year":"2024","unstructured":"Nambu, R. et al. Prognosis of pediatric ulcerative colitis after infliximab failure: A multicenter registry-based cohort study. J. Gastroenterol. Hepatol. 39 (2), 312\u2013318 (2024).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"7","key":"33271_CR4","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1053\/j.gastro.2010.02.047","volume":"138","author":"D Turner","year":"2010","unstructured":"Turner, D. et al. Severe pediatric ulcerative colitis: A prospective multicenter study of outcomes and predictors of response. Gastroenterology 138 (7), 2282\u20132291 (2010).","journal-title":"Gastroenterology"},{"issue":"1","key":"33271_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cgh.2024.08.028","volume":"23","author":"S Honap","year":"2025","unstructured":"Honap, S., Zou, G., Danese, S., Peyrin-Biroulet, L. & Jairath, V. Personalized (N-of-1) clinical trials for inflammatory bowel disease: Opportunities and challenges. Clin. Gastroenterol. Hepatol. 23 (1), 14\u201323 (2025).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"33271_CR6","doi-asserted-by":"publisher","first-page":"103017","DOI":"10.1016\/j.autrev.2021.103017","volume":"21","author":"H Nakase","year":"2022","unstructured":"Nakase, H., Sato, N., Mizuno, N. & Ikawa, Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun. Rev. 21 (3), 103017 (2022).","journal-title":"Autoimmun. Rev."},{"issue":"12","key":"33271_CR7","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1134\/S0006297914120116","volume":"79","author":"AP Toptygina","year":"2014","unstructured":"Toptygina, A. P., Semikina, E. L., Bobyleva, G. V., Miroshkina, L. V. & Petrichuk, S. V. Cytokine profile in children with inflammatory bowel disease. Biochem. (Mosc). 79 (12), 1371\u20131375 (2014).","journal-title":"Biochem. (Mosc)"},{"issue":"1","key":"33271_CR8","doi-asserted-by":"publisher","first-page":"14638","DOI":"10.1038\/s41598-020-71503-y","volume":"10","author":"M Tatsuki","year":"2020","unstructured":"Tatsuki, M. et al. Serological cytokine signature in paediatric patients with inflammatory bowel disease impacts diagnosis. Sci. Rep. 10 (1), 14638 (2020).","journal-title":"Sci. Rep."},{"issue":"12","key":"33271_CR9","doi-asserted-by":"publisher","first-page":"e82300","DOI":"10.1371\/journal.pone.0082300","volume":"8","author":"LA Coburn","year":"2013","unstructured":"Coburn, L. A. et al. High-throughput multi-analyte luminex profiling implicates eotaxin-1 in ulcerative colitis. PLoS One. 8 (12), e82300 (2013).","journal-title":"PLoS One"},{"issue":"6","key":"33271_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/jhg.2014.32","volume":"59","author":"JO Shim","year":"2014","unstructured":"Shim, J. O. & Seo, J. K. Very early-onset inflammatory bowel disease (IBD) in infancy is a different disease entity from adult-onset IBD; One form of interleukin-10 receptor mutations. J. Hum. Genet. 59 (6), 337\u2013341 (2014).","journal-title":"J. Hum. Genet."},{"issue":"1","key":"33271_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.dld.2023.04.017","volume":"56","author":"M Fumery","year":"2024","unstructured":"Fumery, M. et al. Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: A population-based study. Dig. Liver Dis. 56 (1), 21\u201328 (2024).","journal-title":"Dig. Liver Dis."},{"key":"33271_CR12","doi-asserted-by":"crossref","unstructured":"Bertani, L. et al. Serum Interleukin-6 and -8 as predictors of response to Vedolizumab in inflammatory bowel diseases. J. Clin. Med. 9(5), 1323 (2020).","DOI":"10.3390\/jcm9051323"},{"issue":"3","key":"33271_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4103\/sjg.SJG_462_20","volume":"27","author":"Z Wang","year":"2021","unstructured":"Wang, Z., Chen, J., Chen, Z., Xie, L. & Wang, W. Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis may improve via the regulation of IL-23-IL-17 axis and the changes of the proportion of intestinal microflora. Saudi J. Gastroenterol. 27 (3), 149\u2013157 (2021).","journal-title":"Saudi J. Gastroenterol."},{"issue":"2","key":"33271_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/MPG.0000000000002035","volume":"67","author":"D Turner","year":"2018","unstructured":"Turner, D. et al. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An evidence-based guideline from European Crohn\u2019s and colitis organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J. Pediatr. Gastroenterol. Nutr. 67 (2), 257\u2013291 (2018).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"2","key":"33271_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/MPG.0000000000002036","volume":"67","author":"D Turner","year":"2018","unstructured":"Turner, D. et al. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An evidence-based consensus guideline from the European Crohn\u2019s and colitis organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J. Pediatr. Gastroenterol. Nutr. 67 (2), 292\u2013310 (2018).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"1","key":"33271_CR16","doi-asserted-by":"publisher","first-page":"12617","DOI":"10.1038\/s41598-020-69567-x","volume":"10","author":"P Krawiec","year":"2020","unstructured":"Krawiec, P. & Pac-Ko\u017cuchowska, E. Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease. Sci. Rep. 10 (1), 12617 (2020).","journal-title":"Sci. Rep."},{"issue":"6","key":"33271_CR17","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3892\/etm.2015.2370","volume":"9","author":"G Kleiner","year":"2015","unstructured":"Kleiner, G. et al. Pediatric patients with inflammatory bowel disease exhibit increased serum levels of proinflammatory cytokines and chemokines, but decreased circulating levels of macrophage inhibitory protein-1\u03b2, interleukin-2 and interleukin-17. Exp. Ther. Med. 9 (6), 2047\u20132052 (2015).","journal-title":"Exp. Ther. Med."},{"issue":"11","key":"33271_CR18","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1097\/MIB.0b013e3182a563cb","volume":"19","author":"L Ohman","year":"2013","unstructured":"Ohman, L. et al. Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease. Inflamm. Bowel Dis. 19 (11), 2433\u20132439 (2013).","journal-title":"Inflamm. Bowel Dis."},{"issue":"3","key":"33271_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/MPG.0b013e3182979252","volume":"57","author":"V H\u00f6ltt\u00e4","year":"2013","unstructured":"H\u00f6ltt\u00e4, V. et al. Interleukin-17 immunity in pediatric Crohn disease and ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 57 (3), 287\u2013292 (2013).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"5","key":"33271_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41390-019-0486-5","volume":"87","author":"MA Busch","year":"2020","unstructured":"Busch, M. A. et al. Patterns of mucosal inflammation in pediatric inflammatory bowel disease: Striking overexpression of IL-17A in children with ulcerative colitis. Pediatr. Res. 87 (5), 839\u2013846 (2020).","journal-title":"Pediatr. Res."},{"issue":"2","key":"33271_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10620-006-9322-y","volume":"52","author":"KP Reddy","year":"2007","unstructured":"Reddy, K. P., Markowitz, J. E., Ruchelli, E. D., Baldassano, R. N. & Brown, K. A. Lamina propria and circulating interleukin-8 in newly and previously diagnosed pediatric inflammatory bowel disease patients. Dig. Dis. Sci. 52 (2), 365\u2013372 (2007).","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"33271_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/gut.52.1.65","volume":"52","author":"S Fujino","year":"2003","unstructured":"Fujino, S. et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52 (1), 65\u201370 (2003).","journal-title":"Gut"},{"key":"33271_CR23","doi-asserted-by":"publisher","first-page":"1055914","DOI":"10.3389\/fimmu.2022.1055914","volume":"13","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. The role of Th17 cells in inflammatory bowel disease and the research progress. Front. Immunol. 13, 1055914 (2022).","journal-title":"Front. Immunol."},{"issue":"10","key":"33271_CR24","doi-asserted-by":"publisher","first-page":"7390","DOI":"10.4049\/jimmunol.181.10.7390","volume":"181","author":"R Ahrens","year":"2008","unstructured":"Ahrens, R. et al. Intestinal macrophage\/epithelial cell-derived CCL11\/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J. Immunol. 181 (10), 7390\u20137399 (2008).","journal-title":"J. Immunol."},{"key":"33271_CR25","doi-asserted-by":"publisher","first-page":"101516","DOI":"10.1016\/j.smim.2021.101516","volume":"54","author":"KR Martin","year":"2021","unstructured":"Martin, K. R., Wong, H. L., Witko-Sarsat, V. & Wicks, I. P. G-CSF - A double edge sword in neutrophil mediated immunity. Semin Immunol. 54, 101516 (2021).","journal-title":"Semin Immunol."},{"issue":"10","key":"33271_CR26","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00384-008-0509-x","volume":"23","author":"M Lampinen","year":"2008","unstructured":"Lampinen, M., Sangfelt, P., Taha, Y. & Carlson, M. Accumulation, activation, and survival of neutrophils in ulcerative colitis: regulation by locally produced factors in the colon and impact of steroid treatment. Int. J. Colorectal Dis. 23 (10), 939\u2013946 (2008).","journal-title":"Int. J. Colorectal Dis."},{"issue":"11","key":"33271_CR27","doi-asserted-by":"publisher","first-page":"e0288147","DOI":"10.1371\/journal.pone.0288147","volume":"18","author":"A Ott","year":"2023","unstructured":"Ott, A. et al. Serum cytokines MCP-1 and GCS-F as potential biomarkers in pediatric inflammatory bowel disease. PLoS One. 18 (11), e0288147 (2023).","journal-title":"PLoS One"},{"key":"33271_CR28","doi-asserted-by":"crossref","unstructured":"Farooq, M., Khan, A. W., Kim, M. S. & Choi, S. The role of fibroblast growth factor (FGF) signaling in tissue repair and regeneration. Cells 10(11) (2021).","DOI":"10.3390\/cells10113242"},{"issue":"6","key":"33271_CR29","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/ibd.21502","volume":"17","author":"M Lenicek","year":"2011","unstructured":"Lenicek, M. et al. Bile acid malabsorption in inflammatory bowel disease: Assessment by serum markers. Inflamm. Bowel Dis. 17 (6), 1322\u20131327 (2011).","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"33271_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.17219\/acem\/184132","volume":"34","author":"A \u0141ukawska","year":"2025","unstructured":"\u0141ukawska, A. & Mulak, A. Serum fibroblast growth factor 19 level correlates inversely with clinical and endoscopic activity of inflammatory bowel disease. Adv. Clin. Exp. Med. 34 (2), 187\u2013198 (2025).","journal-title":"Adv. Clin. Exp. Med."},{"key":"33271_CR31","doi-asserted-by":"crossref","unstructured":"Li, Z. et al. Angiogenic factors and inflammatory bowel diseases. Biomedicines 13(5) (2025).","DOI":"10.3390\/biomedicines13051154"},{"issue":"10","key":"33271_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/PL00000223","volume":"50","author":"G McCormack","year":"2001","unstructured":"McCormack, G. et al. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm. Res. 50 (10), 491\u2013495 (2001).","journal-title":"Inflamm. Res."},{"issue":"10","key":"33271_CR33","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1136\/jcp.2005.034983","volume":"59","author":"N Ansari","year":"2006","unstructured":"Ansari, N. et al. Comparison of RANTES expression in Crohn\u2019s disease and ulcerative colitis: An aid in the differential diagnosis? J. Clin. Pathol. 59 (10), 1066\u20131072 (2006).","journal-title":"J. Clin. Pathol."},{"issue":"9","key":"33271_CR34","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s000110050618","volume":"49","author":"JP F\u00e4gerstam","year":"2000","unstructured":"F\u00e4gerstam, J. P., Whiss, P. A., Str\u00f6m, M. & Andersson, R. G. Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease. Inflamm. Res. 49 (9), 466\u2013472 (2000).","journal-title":"Inflamm. Res."},{"issue":"5","key":"33271_CR35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/00365521.2017.1403647","volume":"53","author":"Y Nishida","year":"2018","unstructured":"Nishida, Y. et al. Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis. Scand. J. Gastroenterol. 53 (5), 579\u2013585 (2018).","journal-title":"Scand. J. Gastroenterol."},{"issue":"10","key":"33271_CR36","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/jgh.13008","volume":"30","author":"S Sato","year":"2015","unstructured":"Sato, S., Chiba, T., Nakamura, S. & Matsumoto, T. Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis. J. Gastroenterol. Hepatol. 30 (10), 1467\u20131472 (2015).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"7","key":"33271_CR37","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/bcp.14235","volume":"86","author":"L Bertani","year":"2020","unstructured":"Bertani, L. et al. Assessment of serum cytokines predicts clinical and endoscopic outcomes to Vedolizumab in ulcerative colitis patients. Br. J. Clin. Pharmacol. 86 (7), 1296\u20131305 (2020).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"33271_CR38","doi-asserted-by":"crossref","unstructured":"Caviglia, G. P. et al. On-treatment decrease of serum interleukin-6 as a predictor of clinical response to biologic therapy in patients with inflammatory bowel diseases. J. Clin. Med.  9(3) (2020).","DOI":"10.3390\/jcm9030800"},{"issue":"6","key":"33271_CR39","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","volume":"58","author":"A Levine","year":"2014","unstructured":"Levine, A. et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J. Pediatr. Gastroenterol. Nutr. 58 (6), 795\u2013806 (2014).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"2","key":"33271_CR40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","volume":"133","author":"D Turner","year":"2007","unstructured":"Turner, D. et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter study. Gastroenterology 133 (2), 423\u2013432 (2007).","journal-title":"Gastroenterology"},{"issue":"6","key":"33271_CR41","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/ibd.21493","volume":"17","author":"A Levine","year":"2011","unstructured":"Levine, A. et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification. Inflamm. Bowel Dis. 17 (6), 1314\u20131321 (2011).","journal-title":"Inflamm. Bowel Dis."},{"issue":"4","key":"33271_CR42","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/ibd.21088","volume":"16","author":"D Turner","year":"2010","unstructured":"Turner, D. et al. Assessing disease activity in ulcerative colitis: Patients or their physicians? Inflamm. Bowel Dis. 16 (4), 651\u2013656 (2010).","journal-title":"Inflamm. Bowel Dis."},{"key":"33271_CR43","doi-asserted-by":"publisher","first-page":"2098293","DOI":"10.1155\/2017\/2098293","volume":"2017","author":"V Kristensen","year":"2017","unstructured":"Kristensen, V., R\u00f8seth, A., Ahmad, T., Skar, V. & Moum, B. Fecal calprotectin: A reliable predictor of mucosal healing after treatment for active ulcerative colitis. Gastroenterol. Res. Pract. 2017, 2098293 (2017).","journal-title":"Gastroenterol. Res. Pract."},{"issue":"11","key":"33271_CR44","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.7150\/ijms.110452","volume":"22","author":"D Forszt","year":"2025","unstructured":"Forszt, D. et al. The screening assessment of pro-inflammatory, anti-inflammatory, Th1, Th2 and Th17 cytokines in saliva of patients with ischemic stroke. Int. J. Med. Sci. 22 (11), 2686\u20132699 (2025).","journal-title":"Int. J. Med. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33271-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33271-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33271-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T01:03:28Z","timestamp":1769475808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33271-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["33271"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-33271-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The researchers obtained approval from the local bioethics committee (approval number APK.002.409.2020, date: 17.12.2020). The purpose of the study was explained to parents and participants. All legal guardians, as well as the patient in the case of a child aged\u2009>\u200913 years, gave written informed consent to participate in the experiment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical consideration"}}],"article-number":"3353"}}